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Abstract 
Objective: Negative symptoms are currently viewed as having a two-dimensional structure, with 
factors reflecting diminished expression (EXP) and motivation and pleasure (MAP). However, 
several factor-analytic studies suggest that the consensus around a two-dimensional model is 
premature. The current study investigated and cross-culturally validated the factorial structure of 
BNSS-rated negative symptoms across a range of cultures and languages. 
 
Method: Participants included individuals diagnosed with a psychotic disorder who had been 
rated on the Brief Negative Symptom Scale (BNSS) from five cross-cultural samples, with a 
total N = 1,691. First, exploratory factor analysis was used to extract up to six factors from the 
data. Next, confirmatory factor analysis evaluated the fit of five models: 1) a one-factor model, 
2) a two-factor model with factors of MAP and EXP, 3) a three-factor model with inner world, 
external, and alogia factors; 4) a five-factor model with separate factors for blunted affect, 
alogia, anhedonia, avolition, and asociality, and 5) a hierarchical model with two second-order 
factors reflecting EXP and MAP, as well as five first-order factors reflecting the five 
aforementioned domains.  
 
Results: Models with four factors or less were mediocre fits to the data. The five-factor, six-
factor, and the hierarchical 2nd-order five-factor models provided excellent fit with an edge to the 
five-factor model. The five-factor structure demonstrated invariance across study samples. 
 
Conclusions: Findings support the validity of the five-factor structure of BNSS-rated negative 
symptoms across diverse cultures and languages. These findings have important implications for 





Keywords: Negative symptoms; five factors; anhedonia; avolition; asociality; alogia; blunted 
affect; Brief Negative Symptoms Scale (BNSS); confirmatory factor analysis; exploratory factor 
analysis  
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Introduction 
 Early factor-analytic studies indicated that negative symptoms are a domain of 
psychopathology that is distinct from psychosis and disorganization in individuals with 
schizophrenia.1-3 These studies relied on broad-bandwidth rating scales such as the full Positive 
and Negative Syndrome Scale (PANSS) and the Brief Psychiatric Rating Scale (BPRS) that 
assess negative symptoms along with other symptoms of schizophrenia. However, the use of 
broad-bandwidth measures to adjudge the factor structure of negative symptoms is flawed 
because covariance patterns in the symptom data cause negative symptom items to aggregate 
together, making the construct arbitrarily unidimensional. 
Factor analyses evaluating the structure of negative symptoms with narrow-bandwidth 
scales—that is, measures of negative symptoms alone, with no items included from other 
constructs—suggest that the structure of negative symptoms is multidimensional.4 A two-factor 
solution has commonly been reported for a range of narrow-bandwidth measures, including the 
Scale for the Assessment of Negative Symptoms (SANS), Schedule for the Deficit Syndrome 
(SDS), Brief Negative Symptom Scale (BNSS), Clinical Assessment Interview for Negative 
Symptoms (CAINS), and negative symptom items of the PANSS.5-15 The two dimensions reflect: 
1) diminished expressivity (EXP), consisting of alogia and blunted affect items, and 2) 
motivation and pleasure (MAP), consisting of avolition, asociality, and anhedonia.5-12 These 
findings have led the field to widely accept the two-dimensional structure of negative 
symptoms.4 This two-dimensional model has been very influential, impacting important 
decisions, such as how negative symptoms are described in the DSM-5, how treatment targets 
are defined, how scales are scored for statistical analysis, and how studies search for 
pathophysiological mechanisms.13 
 However, the two-dimensional conceptualization of negative symptoms may be 
statistically or theoretically insufficient. Support for the two-dimensional structure comes from 
studies using exploratory factor analysis (EFA), a data reduction method that infers the presence 
of latent factors responsible for shared variance among items in a scale.14-15 EFA is limited in 
that it does not specify an underlying structure of negative symptoms, but rather assumes that 
each item in a scale could be related to each underlying latent factor.15 Prior EFA studies were 
important for generating hypothesis about dimensions in negative symptoms. They are not, 
however, actual tests of the validity of a two-factor structure and their exploratory nature does 
not allow direct assessment of their factorial validity relative to competing factor models of 
negative symptoms.13 Moreover, Garcia-Portilla and colleagues16 using EFA concluded that a 
three-factor structure that distinguished inner-world experiences (i.e., avolition and blunted 
affect) from external features (anhedonia and asociality), and alogia was preferable to a two-
factor model. The three-factor model has yet to be replicated, but it shows that the consensus that 
two factors best describe the multidimensionality of negative symptoms is premature.  
Confirmatory factor analysis (CFA) is required to test competing models and evaluate the 
dimensional structure of BNSS-rated negative symptoms. Published CFA studies have examined 
the SANS, and were problematic because they included items not part of the negative symptom 
construct, which limits conclusions that can be drawn.17-18 Axelrod and colleagues19-20 conducted 
two early CFA studies of negative symptoms measured with the Negative Symptom Assessment 
(NSA). In the first study of a 26-item NSA, they found that a multidimensional model that 
included communication, emotion/affect, social involvement, motivation, retardation, and gross 
cognition as six separable factors best described negative symptoms. In the second study, they 
used a 16-item version of the measure which now excluded items that originally loaded onto the 
“gross cognition” factor. The authors replicated five of the original factors-- communication, 
emotion/affect, social involvement, motivation, and retardation. The statistical fit indices 
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obtained in both studies favored their chosen five or six-factor models over one- to four-factor 
solutions. Their chosen models however proved to be mediocre fits to the data based on 
statistical fit indices. Further, both 26 and 16-item versions of the NSA did not include items that 
assess anhedonia.   
The 2005 NIMH-MATRICS consensus conference on negative symptoms sought to establish the 
scope of negative symptoms in order to foster the development of evidence-based measures and 
treatments for negative symptoms.21 The conference identified affective flattening, alogia, 
asociality, avolition, and anhedonia as domains of negative symptoms. These domains 
subsequently informed the content coverage of the BNSS and the CAINS. Strauss et al.22 
conducted CFA of three current negative symptoms scales, the BNSS (n=192), CAINS (n=400), 
and SANS (n=268). Four competing models were evaluated. The first model was unidimensional 
and evaluated whether all items best reflect a single latent negative symptom construct. The 
second model evaluated the two dimensions identified in prior EFA studies7,11-13, reflecting EXP 
and MAP factors. The third model was a five-factor model, which specified one factor for each 
of the five domains identified in the 2005 NIMH consensus development conference on negative 
symptoms: anhedonia, avolition, asociality, alogia, blunted affect.21 The fourth model was a 
hierarchical five-factor model. It specified two second-order factors reflecting EXP and MAP, as 
well as five first-order factors reflecting the five consensus domains. First-order factors 
represented anhedonia, avolition, and asociality, which were specified to load on the MAP 
second-order factor; and blunted affect and alogia first-order factors were specified to load on the 
EXP second-order factor. The results were consistent across all three of these scales. The one- 
and two-factor models provided poor fit for the data. The five-factor and hierarchical models 
provided excellent fit, with the five-factor model slightly outperforming the hierarchical model 
and being most parsimonious. These findings suggest that the recent trend toward 
conceptualizing negative symptoms in relation to the MAP and EXP does not capture the 
complexity of negative symptoms, which is best represented by the five NIMH consensus 
domains. 
The current study attempted to determine the correct factorial structure of BNSS-rated 
negative symptoms using data obtained across a range of cultures and languages. We took both 
an empirical exploratory (EFA) and a model-based (CFA) approach to determining the correct 
factor structure. A model-based approach allowed 1) a comparison of the NIMH consensus five-
factor model with alternate models including—the unidimensional/one-factor model, MAP/EXP 
two-factor, Garcia-Portilla et al.’s three-factor model, and the hierarchical five-factor model; and 
2) testing the cross-cultural measurement invariance of the correct factor structure using data 
from five samples including N=1,691 participants from Italy, Spain, China, Switzerland, and the 
United States. The EFA extracting one to six factors from the data allowed us to 1) examine the 
relative viability of several factor models (e.g., four-factor and six-factor models) in the absence 
of guiding theory or apriori evidence; 2) determine if CFA and EFA converge to support the 
same factor structure; 3) assess if the preferential loading of BNSS items supports existing 
models; and 4) in the absence of guiding theory determine the loading preference of Item4 “Lack 
of Normal Distress” in fitted factor models.  Although not adjudged as a negative symptom in 
the 2005 NIMH-MATRICS conference, Item4 “Lack of Normal Distress” was included in the 
BNSS because of its association with reduced emotional expression and deficit symptoms. In 
previous factor analytic studies, the item loads with BNSS factors albeit with lower saturation 
than other items.23 EFA was used to adjudicate the correct factor location of this item in the 
BNSS. It was predicted that EFA and CFA will demonstrate preference for a five-factor model of 
BNSS-rated negative symptoms over alternate models. In concert with Strauss et al.22, the five-
factor and hierarchical models were expected to provide excellent fit to the data, with the five-
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factor model producing the best fit. It was further predicted that the preferred factor structure 






The datasets used to investigate the factorial structure of negative symptoms in the 
current study were drawn from several international investigations of the psychometric 
properties of the BNSS and its clinical utility. These included samples obtained from 
collaborations in Italy (n=937), Spain (n=115), China (n=163), and Switzerland (n=119) that 
used versions of the BNSS formally translated into Italian, Spanish, Chinese (simplified script), 
and German respectively.24-27 The study also included a USA-based sample (n=357) obtained 
with the original English version.11 Additional sample details are provided in the Supplement. 
Table 1 summarizes the demographic characteristics and clinical composition of the study 
samples. Participants from Italy, Spain, and the United States were evaluated to ensure that they 
met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for schizophrenia 
or schizoaffective disorder using the Structured Clinical Interview for DSM-IV (SCID). Swiss 
participants were adjudged as meeting DSM diagnostic criteria using the Mini-International 
Neuropsychiatric Interview (MINI). Participants from China were assessed with the International 
Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) criteria.  
 
Procedures 
Each study administered the BNSS as part of broader research aims to illuminate the 
phenomenology and treatment of negative symptoms. Given that investigators in Italy, Spain, 
Switzerland, and China administered translated versions of the BNSS, a standard method of 
translation served to ensure the equivalence of the translated versions to the original English 
version. First, the BNSS was forward translated to the target language. Next, the translated 
version was independently back-translated and forwarded to the scale authors (BK and GS), who 
worked with the translators to reconcile the translation with the original English version.  
The inter-rater reliability of the BNSS was established at each site through the use of 
gold-standard training videos and ratings of face-to-face interviews completed by the BNSS 
authors. All raters completed BNSS training using standardized training materials and received 
feedback from completing ratings on gold-standard videos. Raters in each study had at 
minimum, bachelors-level training and/or extensive experience completing psychiatric 
interviews. BNSS raters in each parent study met minimum standards of inter-rater reliability 
with intraclass correlation coefficients that exceed 0.90 (Table 1). 
 
Data Analysis 
The overall analytic strategy was to establish the factor structure of BNSS-rated negative 
symptoms in a calibration sample and then cross-validate the established factor structure across 
languages and cultures. Rather than test all factor models in every study sample, the decision was 
made to first estimate alternate factor models in a calibration sample and then cross-validate best 
fit models in order to: 1) decrease the number of separate factor models that would need to be 
estimated; and 2) decrease the likelihood that models with apparent fit in one sample but had 
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capitalized on chance (Type I error) are interpreted. The calibration sample included 566 cases 
(60.4%) drawn randomly from the largest study sample, the Italian dataset. The remaining 371 
cases in the Italian dataset were designated as one of the five cross-validation samples; therefore, 
each language and data source served in the cross-validation of the preferred factor structure.  
To examine the fits of evaluated models, BNSS ratings were factor analyzed with model 
estimation methods that are robust to distributional non-normality in BNSS ratings. EFA models 
ranging from one to six classes were estimated first excluding and then including Item 4 “Lack 
of Normal Distress” to identify the item’s preferred factor location. EFAs were completed with 
the oblique Quartimin rotation. Unlike previous EFA studies, the preferred factor structure was 
adjudged by examining pattern loadings and objective fit indices (discussed below). Next, CFA 
was used to test competing hypotheses about the factor structure of negative symptoms. Five 
models estimated included a unidimensional/one-factor, MAP/EXP two-factor, Garcia-Portilla et 
al.’s three-factor, the NIMH consensus five-factor, and the hierarchical five-factor models. Items 
included on each factor within the five models are presented in Table 2. The estimators were the 
weighted least squared estimator with standard errors and mean-and variance adjusted chi-square 
test that use a full-weight matrix (WLSMV), and the maximum likelihood with robust standard 
errors (MLR). All model estimations were carried out in Mplus Version 5.0.28 Model 
modification indices were obtained to assess and evaluate all fixed parameters (e.g., specified 
loading patterns) to determine which fixed parameters if freely estimated would have improved 
the model being evaluated. By convention, modification indices are used jointly with theory to 
guide attempts to re-specify poor fitting models.   
 Several indices served to evaluate the goodness-of-fit of estimated factor models. The 
chi-square (2) test evaluates the degree to which the hypothesized factor structure fits data29; 
however, it is sensitive to large sample sizes that may cause the rejection of well-fitting models. 
The root-mean-square error of approximation (RMSEA)30 measures the discrepancy between the 
hypothesized factor model and the population covariance matrix when the model has unknown 
but optimally-chosen parameter values. RMSEA values of .08 and lower are considered adequate 
fit and values .05 and lower indicate excellent fits31; however, the RMSEA is sensitive to model 
complexity and smaller sample sizes may cause RMSEA to over-reject true population models.29 
The Comparative Fit Index (CFI) and the Tucker Lewis Index (TLI) are incremental fit indices 
that compare the hypothesized factor model with the less restricted nested baseline model.32-33 
The TLI however penalizes overly complex models. CFI and TLI values of .95 and higher are 
considered indicative of strong fitting models.29 The information criteria indices including 
Akaike Information Criteria (AIC), Bayesian Information Criteria (BIC) and the sample-size 
adjusted BIC (aBIC) are used for comparing non-nested models.34-35 Information criteria 
consider the chi-square and the model complexity in penalizing models and therefore favor 
parsimonious models. Models with lower information criteria are preferred. The Standardized 
Root Mean Squared Residual (SRMR) and the Weighted Root Mean Squared Residual (WRMR) 
are residual-based indices based on the difference of the variance-covariance matrix of the 
hypothesized model and that of the observed sample data.28,29 Both measure the average 
difference across all standardized residuals but WRMR uses a variance—weighted approach.28-
29,36 SRMR values range from 0 to 1 with values of 0.08 or lower indicative of good fitting 
models. WRMR values of about 1.00 and lower are considered strong fits.  
 Multi-group CFA was used to assess the measurement invariance of the BNSS-preferred 
factor structure across the multi-national samples. This comprised tests of configural, metric, 
scalar, and residual invariance that are conducted sequentially.37-38 Configural invariance 
requires that items load on the same factor across subsamples. Metric invariance requires that 
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factor loadings be equivalent across the multi-national samples. Scalar invariance requires that 
both factor loadings and intercepts are equivalent across study samples. Residual factorial 
invariance adds an additional constraint requiring that residual variances are equal across 
samples. Changes in chi-square (χ2diff), CFI, TLI, and RMSEA estimates as constraints were 
imposed on the model were used to evaluate the invariance models. CFI change has the most 
empirical support and values not exceeding 0.01 provide evidence that constraints imposed on 
model are tenable.37-39   
Results 
The study aims were addressed in three stages. First, EFA was used to extract up to six 
factors from the BNSS using the calibration sample. Two sets of EFAs were completed at this 
stage—BNSS ratings first excluding, and then including Item4 “Lack of Normal Distress.” Next, 
model-based CFAs were used to compare the relative fits of the one-, two-, three-, five-factor, 
and hierarchical models in the calibration sample. The favored factor models were tested in each 
of the five cross-validation samples. Finally, measurement invariance of the preferred factor 
structure across study samples was sequentially evaluated for metric, scalar, and residual 
invariance.  
  
Table 1 summarizes the characteristics of the study samples. Cronbach’s alpha exceeded 
0.90 in every study sample, suggesting that raters were able to reliable assess negative symptoms 
with the BNSS regardless of the language of administration or participants’ country of origin. 
Save for one participant in the Italian sample who was subsequently excluded from the analysis 
due to missing data, complete ratings were obtained for all BNSS items in all of the study 
samples. The variability in BNSS total score across samples likely reflects the illness acuity of 
participants recruited in the particular parent study. 
 
EFA of the BNSS Calibration Sample 
 The results of EFA runs in the calibration sample are summarized in Table 3. Although 
CFI and TLI estimates were acceptable for one through four-factor models, high RMSEA 
estimates suggested that these were mediocre fits to the data. With or without Item4, the EFA 
five-factor and six-factor models were strong fits to the data with CFI, TLI, RMSEA, and SRMR 
that fell in the excellent-fit range. Without Item4, the AIC and other information criteria favored 
a five-factor model over the six-factor model. Moreover, the six-factor solution produced two 
factors with single items.  
With Item4 included in the model, the information criteria slightly preferred the six-
factor solution. Subsequent examination of the matrix of rotated loadings of the six-factor 
solution showed that all BNSS items including Item4 weakly loaded on the sixth factor with all 
loading coefficients less than an absolute value of 0.11. This suggests that a sixth factor 
contributes little to explaining the pattern of covariances of BNSS items and the six-factor 
solution should be rejected in favor of the more parsimonious five-factor model.  
The rotated five-factor matrices for all factor solutions are presented in Supplemental 
Tables S1-S12. Item4 cross-loaded onto two BNSS factors—Anhedonia and Asociality. 
 
CFA of the BNSS-Rated Negative Symptoms in the Calibration Sample    
The results of the CFAs conducted in the calibration sample are summarized in Table 4. 
All CFA models excluded Item4 given that it was not a recognized negative symptom in the 
NIMH-MATRICS conference. The one-factor, two-factor, and the three-factor models proved to 
be mediocre fits to the data. The one-factor models were a poor fit due to mediocre CFI, 
RMSEA, and WRMR values. Although the CFI and the TLI for the two-factor and three-factor 
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models exceeded the .95 threshold, both were poor fits to the data based on high RMSEA and 
WRMR values.  
 The five-factor and the hierarchical models produced CFI and TLI values that suggest 
strong fit to the data. The RMSEA values for both factor models just fell under the .08 threshold, 
suggesting adequate fits to the data. Both the five-factor and hierarchical models also produced 
WRMR estimates that fell below 1.00, suggesting strong fits to the data.  
The AIC and other information criteria favored the five-factor model and the hierarchical 
model over the one-, two-, and three-factor models. The information criteria slightly favored the 
five-factor model over the hierarchical model.   
 
Cross-Validation in Multi-National Samples 
Given their strong performance in the calibration sample, we tested both the five-factor 
and hierarchical models in cross-validation samples. Table 4 summarizes the results of cross-
validating the BNSS five-factor and the hierarchical models. Both factor models proved to be 
strong fits to the data based on CFI and TLI estimates that far exceeded the 0.95 threshold in 
each sample. Across samples, the RMSEAs frequently fell below the .08 threshold that would 
suggest an adequate fit. The exceptions were the five-factor models in the Chinese and American 
sample and the hierarchical model in the Chinese sample. Like the CFI and TLI however, the 
WRMR suggested strong fits for both models in all samples.  
 The AIC and other information criteria produced values that were lower for the 
five-factor model than the hierarchical model in all of the samples. This suggests that although 
both the five-factor and hierarchical models are cross-culturally valid, the five-factor model is 
slightly stronger. Supplemental Table S13 includes internal consistency estimates of the five 




Assessment of Measurement Invariance across Samples 
 We conducted tests of factorial invariance among the five multinational samples using 
the five-factor model. The analysis was completed on the full study sample. Due to the unequal 
group sizes, which may bias estimates in favor of the larger Italian and USA-based samples, the 
analysis was also completed in a subsample of 575 individuals with 115 individuals from each 
subsample. To this end, 115 individuals were randomly drawn from the Italian, Chinese, Swiss, 
and American samples, whereas the entire Spanish sample was included. The results were not 
remarkably different. Table 5 summarizes all the fit indices of the measurement invariance 
model. Fit values from the configural model showed that the five-factor model held across all 
samples with CFI and TLI that exceed 0.99 and RMSEA falling below the 0.08 threshold. Metric 
invariance (equivalence of factor loadings) was similarly supported with CFI and TLI that 
exceed 0.99 and RMSEA close to 0.08. Scalar (equivalence of factor loading and intercepts) and 
residual (equivalence of loadings, intercepts, and factor residual variances) invariance was 
supported by high CFI and TLI values that decreased by less than 0.01 from the configural and 
metric models. The RMSEA value suggested a slight loss of absolute model fit however when 
assumptions of scalar invariance are violated.  Using modification indices, it was determined that 
Item2 in the Italian sample had a higher intercept than in the other samples. When Item2 was 
freely estimated in the multigroup CFA, the RMSEA for scalar invariance model improves 
(CFI=0.989, TLI=0.998, RMSEA=.082). This suggests that Italian participants (all outpatients) 
tended to be rated as more impaired on Item2 “Frequency of Pleasurable Activities” compared to 
participants in other samples, particularly the Chinese sample (inpatients/outpatients).    




CFA was used to investigate latent dimensions in BNSS-rated negative symptoms. BNSS 
data was analyzed from five samples of different cultures and languages to determine the BNSS 
factorial structure. In both EFA and CFA runs, the five-factor model proved to be the preferred 
structure of BNSS-rated negative symptoms. The hierarchical 2nd-order five-factor model also 
provided excellent fit, similarly supporting its factorial validity. Although a two-factor model 
consistent with the MAP and EXP dimensions emerged from the EFA, this was rejected on the 
basis of its poor objective fit to the data. Previous studies erroneously accepted this solution for 
its parsimony and logic in the absence of objective fit indices. Evidence of factorial invariance 
across multinational samples indicated that the five-factor loading pattern holds cross-culturally 
and can be studied across translations. The current study extends evidence of the five-factor 
model of negative symptoms across five cultures and languages using translated or original 
English versions of the BNSS. 
There are several important implications for these findings. First, the five-factor structure 
is not culturally-bound. This suggests that these five domains reflect core processes inherent to 
the diagnosis that are not dependent on language or cultural influences. Second, these results also 
demonstrate that not only are early views of negative symptoms as a single construct inaccurate, 
but the current trend toward viewing negative symptoms as a two-dimensional construct is also 
not fully justified. Rather, negative symptoms are best conceptualized in relation to the five 
negative symptom domains identified in the 2005 NIMH consensus conference: anhedonia, 
avolition, asociality, alogia, and blunted affect.21 The two-dimensional conceptualization has had 
an important, but statistically unjustified influence on the field. For example, the DSM-5 
describes negative symptoms in relation to the broad MAP and EXP dimensions, rather than the 
five consensus domains. This procedure may lead to underspecified diagnoses that do not capture 
the granularity of the construct. Future versions of the DSM may need to list and define each 
domain separately. Failure to do so will probably hamper efforts to identify the psychological 
and pathophysiological mechanisms of each domain. Treatments may also have differential 
efficacy for these five domains, and failing to evaluate the five domains separately may prevent 
observation of meaningful treatment effects that are domain-specific, rather than tied to the two 
broader dimensions. Treatment development efforts will be advanced by pharmacological and 
psychological treatments targeted to specific factors. Clinical trials testing such treatments 
should specify which of the five factors represent the primary target(s)/outcome(s). 
The NIMH RDoC initiative provides a framework for exploring neurobiological 
processes associated with aspects of “positive valence systems” and “social processes” that map 
onto these five clinical domains.40-41 Some of these pathophysiological processes may be broadly 
related to the MAP and EXP dimensions, whereas others may be tied to one of the five domains 
more specifically. Future investigations are needed to explore pathophysiology tied to each 
domain to promote targeted treatment development. Such trials should focus on one of the 
domains specifically. It is possible that trials already conducted have observed treatment effects, 
but these were masked by procedures for calculating overly broad scores. Reanalysis of large 
past studies with appropriate instruments may be warranted, and interpretation of future 
treatment trials would be strengthened by calculating scores for each of the five domains, rather 
than a global total score, or MAP and EXP dimensional scores, alone.  
Strauss et al.22 demonstrated that other measures besides the BNSS—the SANS and the 
CAINS—similarly captured the five domains. Developers of future negative symptom scales 
should endeavor to generate candidate items that capture each of these five domains. This will 
support a more focused creation of items for initial review and psychometric testing. It will also 
Ahmed et al.       10 
 
ensure that rating scales are brief yet comprehensive in their coverage of negative symptoms. 
The factorial validity of the hierarchical model also has implications for scale development. The 
MAP and EXP 2nd-order factors represent higher-order broad dimensions that subsume the 
lower-order, narrow five domains. Measures like the BNSS and the CAINS that capture both 
narrow and broader facets of negative symptoms are potentially more comprehensive in their 
scope and maintain the relative advantages of capturing both broad and narrow facets of negative 
symptoms. Such measures have potentially better reliability and fidelity given that more items 
assess the broader, higher-order dimensions, and the narrow bandwidth domains within broad 
dimensions are inter-correlated.42 These measures also maintain the relative advantage of narrow 
bandwidth assessments including: 1) severity ratings and differences on specific domains are 
captured; 2) the specific effects of narrow-band domains within broader dimensions on external 
variables can be captured when the same effects may be attenuated in broader dimensions; and 3) 
better interpretability when specific narrow facets are linked to external variables.42-43 
     The use of a multinational sample to cross-validate the five-factor and hierarchical 
five-factor models lends strong credence to conclusions about the factorial structure of negative 
symptoms. The results suggest that the five-factor model is unbounded by culture, language, or 
setting. It represents rather a structure of negative symptoms that is pervasive, universal, and 
likely linked to distinct psychological and/or pathophysiological processes found across cultures. 
The strong cross-validation results provide additional evidence of the excellent psychometric 
characteristics of the translated versions of the measure. Practically, these findings suggest that 
the five factors are domains that exist globally and are assessable in different languages with 
good reliability and validity. Observed differences in the intercepts of Item2 is informative rather 
than prohibitive of the use of the BNSS cross-culturally. It may suggest that cultural norms 
impact the definition of “normal” versus “impaired” in adjudging the frequency of pleasurable 
activities. Sociocultural and contextual factors have been shown to influence the expression and 
clinical trajectory of schizophrenia symptoms.44-47 It is therefore possible that the frequency of 
pleasurable activities exhibits cultural and contextual variation that warrants further study. 
The current study did not evaluate the measurement invariance of the five-factor model 
across other sources of symptom heterogeneity such as sex, diagnosis, and illness stage. These 
were adjudged as worthwhile for further validation of the five-factor model but beyond the scope 
of the current study. In addition, the study did not examine the five factors in relation to the 
origin or form of negative symptoms.48-49 A next step is to determine if the five-factor model is 
valid regardless of sex, negative symptom type, illness stage, or illness severity. Any 
determination of equivalence or non-equivalence of the five domains would be informative about 
the phenomenology of negative symptoms.  
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Table 1. Characteristics of the Brief Negative Syndrome Scale (BNSS) Study Samples used in the Analyses 
Author, Year Source Language   n Population Setting  Male Age   BNSS                Internal    ICC 
           % M(SD)      M(SD)             Consistency  
Mucci et al., 2015 Italy Italian   937 Schizophrenia Outpatient  69.6 40.1(10.7)     35.83(18.04) 0.994    0.98 
 
Mane et al., 2014 Spain Spanish   115 Schizophrenia Outpatient  67.0 33.9(8.82)    27.47(13.65) 0.922    0.97 
 
Yao et al., 2014 China Chinese   163 Schizophrenia Inpatient & 54.6 45.3(8.6)    18.25(12.67) 0.933    0.93 
       Outpatient 
 
Bishof et al., 2016     Switzerland    German   119 Schizophrenia Inpatient & 72.3 32.4(10.6)    27.34(15.5) 0.944    0.97 
     Schizoaffective Outpatient 
 
Strauss et al., 2012 USA English   357 Schizophrenia Outpatient  67.2 40.6(11.9)  21.4(15.9)  0.934    0.96 
     Schizoaffective 
     
Notes. ICC=Intraclass Correlation Coefficient. Internal consistency values are Cronbach’s alpha estimates. When a scale  
has more than five response categories, Cronbach’s alpha produces robust estimates of internal consistency comparable to other methods  
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Table 2. Confirmatory factor Analysis Models of the Brief Negative Symptom Scale (BNSS) 
BNSS Items and Domains  CFA Models 
 1-factor 2-factor 3-factor 5-factor 5-factor Hierarchical 
         1st order 2nd order 
Anhedonia       
   1. Intensity of past-week pleasure 1 1 1 1 1 1 
   2. Frequency of past-week pleasure 1 1 1 1 1 1 
   3. Intensity of expected pleasure 1 1 1 1 1 1 
Asociaility       
   5. Asociality behavior 1 1 1 2 2 1 
   6. Asociality internal experience 1 1 1 2 2 1 
Avolition       
   7. Avolition behavior 1 1 2 3 3 1 
   8. Avoliton internal experience 1 1 2 3 3 1 
Blunted Affect       
   9. Facial expression 1 2 2 4 4 2 
   10. Vocal expression 1 2 2 4 4 2 
   11. Expressive gestures 1 2 2 4 4 2 
Alogia       
   12. Quality of speech 1 2 3 5 5 2 
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Table 3. Model Fit Results of the Exploratory Factor Analysis of BNSS Items 
Italian Calibration 
Sample LL k AIC BIC aBIC Chi-Square k CFI TLI RMSEA SRMR 
Item 4 Excluded            
1-Factor -9,660.29 84 19,488.58 19,853.02 19,586.36 X2(54)=5525.09, p < 0.001 12 0.971 0.965 0.423 0.127 
2-Factor -9,080.54 95 18,351.08 18,763.24 18,461.66 X2(43)=3311.48, p < 0.001 23 0.983 0.974 0.366 0.066 
3-Factor -8,874.36 105 17,958.72 18,414.27 18,080.95 X2(33)=2113.90, p < 0.001  33 0.989 0.978 0.334 0.050 
4-Factor -8,575.45 114 17,378.89 17,873.49 17,511.60 X2(24)=829.02, p < 0.001 42 0.996 0.988 0.243 0.022 
5-Factor -8,512.69 122 17,269.39 17,798.70 17,411.40 X2(16)=53.90, p < 0.001 50 1.000 0.999 0.065 0.005 
6-Factor -8,516.94 129 17,291.88 17,851.56 17,442.05 X2(9)=24.33, p = 0.004 57 1.000 0.999 0.055 0.004 
Item 4 Included       
 
    
1-Factor -10,563.52 91 21,309.03 21,703.85 21,414.96 X2(65)=5842.81, p < 0.001 13 0.970 0.964 0.396 0.119 
2-Factor -9,967.65 103 20,141.30 20,588.18 20,261.20 X2(53)=3317.09, p < 0.001 25 0.983 0.975 0.330 0.061 
3-Factor -9,672.65 114 19,573.29 20,067.89 19,705.99 X2(42)=2005.66, p < 0.001 36 0.990 0.981 0.287 0.047 
4-Factor -9,591.27 124 19,430.54 19,968.52 19,574.88 X2(32)=651.91, p < 0.001 46 0.997 0.992 0.185 0.021 
5-Factor -9,565.03 133 19,396.05 19,973.08 19,550.87 X2(23)=74.55, p < 0.001 55 1.000 0.999 0.063 0.007 
6-Factor -9,529.95 141 19,341.89 19,953.64 19,506.03 X2(15)=38.65, p < 0.001 63 1.000 0.999 0.053 0.006 
Note. LL = loglikelihood; k = number of free parameters; AIC = Akaike Information Criterion; BIC=Bayesian Information Criterion, aBIC = sample size adjusted BIC;  
CFI = Comparative Fit Index; TLI = Tucker Lewis Index; RMSEA = Root Mean Square error of Approximation; SRMR= Standardized Root Mean Square Residual; WRMR = Weighted Root 
Mean Square Residual. Both Weighted Least Square (WLSMV) and Maximum Likelihood (MLR) estimators were used in the analyses. 
Chi-Square for the Baseline EFA model with item4 excluded: X2(66) = 190,846.57, p < 0.0001  
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Table 4. Confirmatory Factor Analysis of BNSS Items: Model Fit Results  
 LL k AIC BIC aBIC Chi-Square CFI TLI RMSEA WRMR 
 Italian  Calibration Sample           
1-Factor -9,659.56 84 19,487.13 19,851.57 19,584.91 X2(8)=818.89, p<0.001 0.944 0.965 0.423 4.727 
2-Factor -9,188.17 85 18,546.35 18,915.13 18,645.29 X2(13)=660.10, p<0.001 0.955 0.983 0.297 2.924 
3-Factor -9051.64 87 18277.27 18654.73 18378.54 X2(11)=548.36, p<0.001 0.963 0.983 0.294 2.734 
5-Factor -8715.77 94 17619.54 18027.36 17728.96 X2(19)=77.43, p<0.001 0.996 0.999 0.074 0.487 
2nd-Order 5-Factor -8909.74 86 17991.48 18364.60 18091.59 X2(15)=93.26, p<0.001 0.995 0.998 0.080 0.878 
Cross Validation Samples  
5-Factor Model           
Italian Sample -5,801.92 107 11,817.86 12,236.89 11,897.42 X2(18)=50.49, p=0.001 0.997 0.999 0.070 0.399 
American Sample -5,222.13 94 10,632.25 10,996.76 10,698.55 X2(19)=105.47, p=0.000 0.989 0.995 0.110 0.709 
Spanish Sample -2,162.97 91 4,507.94 4,779.45 4,491.48 X2(19)=34.30, p=0.017 0.994 0.998 0.074 0.385 
Swiss Sample -1,701.47 91 3,584.94 3,837.84 3,550.15 X2(12)=12.69, p=0.3919 1.000 1.000 0.022 0.309 
Chinese Sample -2,055.19 88 4,286.38 4,558.63 4,280.04 X2(18)=48.07, p<0.001 0.989 0.996 0.101 0.468 
Cross Validation Samples 
2nd Order 5-Factor           
Italian Sample -5,951.24 99 12,100.49 12,488.20 12,174.10 X2(13)=28.48, p=0.008 0.998 0.999 0.057 0.502 
American Sample -5,288.10 86 10,748.20 11,081.69 10,808.85 X2(17)=63.49, p=0.000 0.994 0.997 0.088 0.824 
Spanish Sample -2,254.80 84 4,677.61 4,928.23 4,662.42 X2(16)=20.11, p=0.215 0.998 0.999 0.042 0.462 
Swiss Sample -1754.72 83 3,675.43 3,906.10 3,643.70 X2(12)=27.43, p=0.007 0.996 0.997 0.084 0.682 
Chinese Sample -2,168.61 77 4,491.24 4,729.46 4,485.69 X2(15)=83.38, p<0.001 0.975 0.990 0.167 0.942 
Note. LL = loglikelihood; k = number of free parameters; AIC = Akaike Information Criterion; BIC=Bayesian Information Criterion, aBIC = sample size adjusted BIC;  
CFI = Comparative Fit Index; TLI = Tucker Lewis Index; RMSEA = Root Mean Square error of Approximation; WRMR = Weighted Root Mean Square Residual;  
Preferred factor structures in the calibration sample based on fit indices are presented in bold font.  
Chi-Square for the Baseline Model: X2(5)=14,458.07, p < 0.001 (Item 4 excluded). 
Chi-Square for the Baseline Model: X2(6)=14,953.44 , p < 0.001 (Item 4 included).    
Both Weighted Least Square (WLSMV) and Maximum Likelihood (MLR) estimators were used in the analyses. Monte Carlo-based numerical integration was used in the estimation of 
models to ease computation time. The number of Monte Carlo generated integration points ranged from 5,000 to 6,000. 
Chi-Square for the Baseline model in the Italian sample: X2(5) = 9,279.67, p < 0.001  
Chi-Square for the Baseline model in the American sample: X2(9) = 7885.97, p < 0.001  
Chi-Square for the Baseline model in the Spanish sample: X2(7) = 2,531.37, p < 0.001 
Chi-Square for the Baseline model in the Swiss sample: X2(8) = 4,029.90, p < 0.001  
Chi-Square for the Baseline model in the Chinese sample: X2(6) = 2,760.20, p < 0.001  
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Difference Test CFI CFI Change TLI TLI Change RMSEA 
Configural Model X2(87)=252.36, p<0.0001 -- 0.996  0.999  0.074 
Metric Invariance X2(88)=304.29, p<0.0001 X2(27)=121.44, p<0.0001 0.995 0.001 0.998 0.001 0.083 
Scalar Invariance X2(164)=805.06, p<0.0001 X2(114)=704.40, p<0.0001 0.986 0.010 0.997 0.002 0.107 
Residual Invariance X2(163)=681.81, p<0.0001 X2(36)=282.13, p<0.0001 0.988 0.008 0.998 0.001 0.090 
        
Note. N =1,691. CFI = Comparative Fit Index; TLI = Tucker Lewis Index; RMSEA = Root Mean Square error of Approximation;  
Chi-Square for the Baseline model: X2(32) = 44,760.07, p < 0.0001  
 
 
